Speaker Name: Prof. Tina Vilsboll, Clinical Professor and Head of Clinic Steno Diabetes Centre, Copenhagen, Denmark.

Access the expert-led discussion to:

• Review the interrelationship between microvascular and macrovascular complications in T2DM.
• Understand the role of SGLT2i in reducing CV and renal risk beyond glycemic control.
• Examine the clinical utility of GLP-1 RAs for HbA1c reduction, weight management, and organ protection.
• Assess the therapeutic impact of Tirzepatide on glycemic control and body weight.
• Recognize emerging advances in incretin-based therapies focused on efficacy and tolerability.